Elliot S Barnathan
Overview
Explore the profile of Elliot S Barnathan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1861
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gibson C, Bahit M, Mehran R, Mehta S, Lamee R, Goto S, et al.
Am Heart J
. 2025 Feb;
285:21-28.
PMID: 39986336
Background: Despite current antiplatelet therapy, patients remain at risk of recurrent ischemic events after acute coronary syndromes (ACS), which may reflect persistently elevated thrombin generation. Factor XIa inhibition reduces thrombin...
2.
Yuan Z, Levitan B, Deng H, Szarek M, Bauersachs R, Berkowitz S, et al.
J Am Heart Assoc
. 2024 Apr;
13(8):e032782.
PMID: 38563380
Background: The VOYAGER PAD (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of...
3.
Hsia J, Spyropoulos A, Piazza G, Weng S, Dunne M, Lipardi C, et al.
Thromb Haemost
. 2023 Nov;
124(7):649-655.
PMID: 37995748
Background: We conducted a prespecified meta-analysis of two randomized, placebo-controlled trials of rivaroxaban 10 mg daily in prehospital patients with acute coronavirus disease 2019 (COVID-19). Individually, the trials had limited...
4.
Piazza G, Spyropoulos A, Hsia J, Goldin M, Towner W, Go A, et al.
Circulation
. 2023 May;
147(25):1891-1901.
PMID: 37154020
Background: COVID-19 (coronavirus disease 2019) is associated with heightened risks of venous and arterial thrombosis and hospitalization due to respiratory failure. To assess whether prophylactic anticoagulation can safely reduce the...
5.
Volkl A, Moore K, Haskell L, Barnathan E
Am J Cardiovasc Drugs
. 2023 Apr;
23(3):247-255.
PMID: 37115488
Patients with chronic kidney disease are at an increased risk of venous thromboembolism (VTE). The factor Xa inhibitor rivaroxaban has been shown to provide similar efficacy and a lower risk...
6.
Harman N, Gorst S, Williamson P, Barnathan E, Baughman R, Judson M, et al.
Sarcoidosis Vasc Diffuse Lung Dis
. 2023 Feb;
39(3):e2022030.
PMID: 36791046
Background: Pulmonary sarcoidosis is a rare granulomatous disease of unknown aetiology. Heterogeneity in the outcomes measured in trials of treatment for pulmonary sarcoidosis has impacted on the ability to systematically...
7.
Spyropoulos A, Raskob G, Spiro T, Lu W, De Sanctis Y, Albanese J, et al.
TH Open
. 2022 Oct;
6(4):e304-e308.
PMID: 36299620
This post hoc subgroup analysis examined efficacy and safety outcomes with extended thromboprophylaxis rivaroxaban compared with in-hospital enoxaparin in 2,078 patients from the MAGELLAN study who had a hospitalization for...
8.
Raskob G, Ageno W, Albers G, Elliott C, Halperin J, Maynard G, et al.
J Am Heart Assoc
. 2022 Oct;
11(20):e026229.
PMID: 36205248
Background Venous thromboembolism (VTE) often occurs after hospitalization in medically ill patients, but the population benefit-risk of extended thromboprophylaxis remains uncertain. Methods and Results The MARINER (Medically Ill Patient Assessment...
9.
Spyropoulos A, Goldin M, Ageno W, Albers G, Elliott C, Hiatt W, et al.
TH Open
. 2022 Sep;
6(3):e177-e183.
PMID: 36046208
The MARINER trial evaluated whether postdischarge thromboprophylaxis with rivaroxaban could reduce the primary outcome of symptomatic venous thromboembolism (VTE) or VTE-related death in acutely ill medical patients at risk for...
10.
Spyropoulos A, Raskob G, Cohen A, Ageno W, Weitz J, Spiro T, et al.
Circulation
. 2022 Apr;
145(19):1471-1479.
PMID: 35389229
Background: Extended thromboprophylaxis has not been widely implemented in acutely ill medical patients because of bleeding concerns. The MAGELLAN (Multicenter, Randomized, Parallel Group Efficacy and Safety Study for the Prevention...